HIGHLIGHTS
- who: Sarra Mestiri and colleagues from the University of Calgary, Canada have published the article: Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study, in the Journal: (JOURNAL)
- what: This is the first pilot study that highlights the interpersonal heterogeneity of the humoral and cellular responses to the BNT162b2 vaccine.
- how: Observational data showed that BNT162b2 is highly effective in preventing SARS-CoV-2 infection related hospitalization and death . The authors explored the feasibility and efficacy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.